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Plasma levels of Galectin-9 reflect 
disease severity in malaria infection
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Abstract 
Background: Galectin‑9 (Gal‑9) is a β‑galactoside‑binding lectin that interacts with sugar moieties on glycoproteins 
and glycolipids of cells and pathogens. Gal‑9 is known as an immune modulator that induces cell death via interac‑
tion with T cell immunoglobulin and mucin domain‑3 (Tim3), a co‑inhibitory receptor, and it inhibits production of 
several pro‑inflammatory cytokines (TNF, IL‑6 and IL‑1α) and enhances production of IL‑10. To understand the immune 
pathology of malaria, the Gal‑9 in plasma was measured.
Methods: Plasma samples and clinical parameters were obtained from 50 acute malaria cases (nine severe and 41 
uncomplicated cases) from Thailand at three time points: day 0, day 7 and day 28. Gal‑9 levels were determined by 
ELISA. A total of 38 species of cytokines and chemokines were measured using a BioPlex assay.
Results: Gal‑9 levels were higher at day 0 compared to day 7 and day 28 (P < 0.0001). Gal‑9 levels were also higher 
in severe malaria (SM) cases compared to uncomplicated (UM) cases at day 0 and day 7 (923 vs 617 pg/mL; P = 0.03, 
and 659 vs 348 pg/mL; P = 0.02 respectively). Median Gal‑9 levels were higher in patients with blood urea nitrogen 
to creatinine ratio (BUN/creatinine) ≥20 (mg/dL) than in patients with BUN/creatinine <20 (mg/dL) at day 0 (817.3 
vs 576.2 pg/mL, P = 0.007). Gal‑9 was inversely significantly correlated with chloride levels in both SM and UM cases 
(rs = −0.73 and rs = −0.46, respectively). In both UM and SM cases, Gal‑9 was significantly associated with pro‑ and 
anti‑inflammatory cytokines and chemokines such as TNF, IL‑6, IFN‑α2, IFN‑γ, IL‑1Ra and IL‑10. These correlations were 
observed at day 0 but disappeared at day 28.
Conclusions: Gal‑9 is released during acute malaria, and reflects its severity. This elevation of Gal‑9 in acute malaria 
infection raises the possibility of its role in termination of the immune response by binding to Tim‑3, a receptor of 
Gal‑9.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Malaria infection is still a big challenge for public health; 
around 214 million new cases of malaria worldwide 
occurred in 2015 (range 149–303 million) [1]. Plamos-
dium falciparum is responsible for the most severe cases 
of malaria and the greatest number of deaths. Detection 
and monitoring of severe cases are remaining issues for 
patient treatment [2].
Galectin-9 (Gal-9) is member of the galectin family of 
β-galactoside-binding animal lectins with a conserved 
carbohydrate recognition domain (CRD) [3]. Gal-9 was 
first described as an eosinophilic chemoattractant [4]. 
Gal-9 is presumed to bind a variety of molecules includ-
ing glycoproteins and glycolipids of immune cells and 
pathogens [5]. These binding properties exert a variety 
of physiological and pathological functions such as cell 
differentiation, adhesion, aggregation, and cell death [6]. 
The elevation of plasma Gal-9 levels during acute human 
immunodeficiency virus (HIV) infection followed by a 
rapid decrease after anti-retroviral therapy was reported 
[7, 8]. Increase in plasma Gal-9 has also been seen dur-
ing acute dengue virus infection [9]. Gal-9 inhibits 
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production of several pro-inflammatory cytokines (TNF, 
IL-6, IL-1α) and enhances production of IL-10 [10]. These 
cytokines are believed to be involved in pathophysiology 
of malaria [11–13]. Recent findings of co-inhibitory or 
immune checkpoint receptors have been giving a novel 
insight into immune regulation. Because these recep-
tors have a critical role in the maintenance of immune 
homeostasis: their expression on effector T cells ensures 
the proper contraction of effector T cells responses and 
their expression on regulatory T (Treg) cells guarantees 
the proper function of Treg cells to control effector T 
cells [14, 15].
It has been reported that PD1, a co-inhibitory receptor 
play a major role for inactivating a protective immunity 
in malaria infection in mice [16]. Gal-9 binds to T cell 
immunoglobulin and domain 3 (Tim-3) a co-inhibitory 
receptor, and that binding can ameliorate experimen-
tal autoimmune encephalomyelitis (EAE) by inducing 
cell death in Tim-3+ Th1 cells [17, 18]. Gal-9 also regu-
lates activated CD8+ T cells [19], which increase dur-
ing malaria [20]. Activation of CD8+ T cells these cells 
is considered as a risk factor of anemia in severe malar-
ial [21]. These emerging regulatory activities of Gal-9 
involving co-inhibitory receptors took us to investigate 
Gal-9 in malaria, though how Tim-3 functions to deter-
mine effector T cell responses is not yet well clarified 
[15]. Recently expression of Gal-9 and Tim-3 was demon-
strated in lung, mediastinal lymph nodes and liver tissues 
in murine malaria model [22, 23]; however, the plasma 
levels of Gal-9 in human malaria patients has not been 
evaluated yet.
In this study, the plasma levels of Gal-9 in malaria 
patients were measured at three time points (days 0, 
7 and 28) to examine its kinetics and association with 
cytokines, chemokines and clinical parameters.
Methods
Study subjects
Samples at three time points (day 0, day 7 and day 28) 
were obtained from 50 malaria patients, of which 41 were 
acute uncomplicated falciparum malaria (UM) and nine 
were severe falciparum malaria (SM) cases. The median 
age of patients enrolled was 23 (range 15–50) years old. 
There were 29 males and 21 females. Patient body tem-
peratures were >38.5  °C upon admission. Diagnosis was 
performed by thick and thin blood smear in patients 
presenting malaria symptoms and malaria cases were 
defined by positive asexual forms of P. falciparum. Cat-
egorization of malaria cases was performed using WHO 
criteria [24]. Blood was collected in EDTA-containing 
tubes and centrifuged at 3000 rpm for 10 min. Obtained 
plasma was aliquoted and stored at −80 °C until use. On 
day 0, blood was collected and all patients were initi-
ated on treatment with artemisinin-based combination 
therapy (ACT). Patients were followed up until day 28 
according to the protocol.
Clinical processing
At enrollment, clinical information was taken and 
entered in standardized forms. Clinical and bedside 
physical examinations were performed. Complete blood 
counts (CBC) in addition to kidney and liver function 
tests were examined.
Biomarker measurement
Gal-9 concentration in plasma was measured using an 
ELISA (Galpharam Co. Ltd., Takamatsu, Japan) as pre-
viously described [9]. Microplates with 96 wells were 
coated with anti-human Gal-9 monoclonal antibody 
(9S2-3), blocked with 5 % fetal bovine serum in PBS, then 
incubated with the test sample (eightfold diluted plasma) 
for 1 h at RT with continuous shaking at 225 rpm. After 
several washing steps, Gal-9 remaining in the wells was 
recognized by a polyclonal anti-human Gal-9 antibody 
conjugated with biotin using EZ-Link Sulfo-NHS-Biotin 
reagent (Pierce). Quantification was performed by incu-
bating wells with streptavidin-conjugated horseradish 
peroxidase (Invitrogen, Tokyo, Japan) and the colorimet-
ric substrate tetramethylbenzidine (KPL, Gaitherburg, 
MD); then, the optical density was read with a microplate 
spectrophotometer (Bio-Rad).
Thirty-eight cytokine and chemokine species were 
measured using a commercially available kit (Milliplex 
Human Cytokine and Chemokine multiplex assay kit, 
Merck Millipore, Billerica, MA, USA) by Luminex meth-
ods as previously [9]. The assay was performed accord-
ing to manufacturer’s instructions and the concentrations 
of cytokines/chemokines were calculated by comparing 
reads with a 5-parameter logistic standard curve using a 
Bioplex-200 instrument (Bio-Rad, Hercules, CA, USA).
Statistical analysis
The distribution of data did not generally show a nor-
mal distribution by using the Kolmogorov–Smirnov test. 
Therefore, the data were expressed as the median and 
range. Friedman test, a non-parametric statistical test, 
was used to assess differences of Gal-9 and other bio-
markers levels between different time points. The Mann–
Whitney test, also a non-parametric test, was used to 
assess differences in biomarkers and clinical parameters 
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between SM and UM cases. Correlation was assessed 
using Spearman’s rank correlation coefficient test. 
These statistical analyses were performed using Graph-
Pad Prism 6 software (GraphPad Software, San Diego, 
CA, USA). A significant difference was assumed when 
P < 0.05.
Results
Clinical parameter profiles in uncomplicated and severe 
malaria cases
The median of haemoglobin were not significantly differ-
ent between UM and SM cases at day 0 (Table 1). How-
ever, at day-7, the median haemoglobin level in SM cases 
was significantly lower compared to UM cases. Direct bil-
irubin median levels were higher in SM cases compared 
to UM cases at day 0 and day 7. Median platelet level was 
significantly lower at day 0 in SM compared to UM cases. 
The median levels of creatinine, BUN and AST level were 
significantly higher in SM cases compared to UM at day 
0. Median levels of sodium and bicarbonate were lower in 
SM cases compared to UM at day 0 (Table 1).
Kinetic changes in plasma levels of galectin‑9 
and description of its levels in uncomplicated and severe 
malaria cases
Median plasma levels of Gal-9 were significantly elevated 
in malaria patients at day 0 (686 pg/mL) compared to day 
7 (398 pg/mL) and day 28 (243 pg/ml). The median lev-
els of Gal-9 on day 7 was found to be higher compared 
to day 28 but the difference was not significant (Fig. 1a). 
Median levels of Gal-9 were significantly higher in SM 
compared to UM at day 0 (923 pg/mL vs 617 pg/mL) and 
day 7 (659 pg/mL vs 348 pg/mL). At day 28, there was no 
significant difference in the Gal-9 levels between the two 
groups (Fig. 1b).
Kinetic changes of other biomarkers
Among the 38 biomarkers measured, pro-inflammatory 
cytokines of IFN-α2, IL-1α, TNF and IL-6, Th1-related 
cytokine of IFN-γ, regulatory cytokines of IL-10 and IL-
1Ra, growth cytokines of G-CSF, GM-CSF, EGF, FGF-2 
and VEGF, and chemokines of IP-10, MIP-1α, MIP-β, 
MCP-1, IL-8, eotaxin, GRO, Fractalkine and MDC were 
detectable. All of them showed significant difference at 
day 0 compared to day 7 or day 28 except VEGF, MIP-1α, 
eotaxin and GRO (Table  2). In addition, the levels of 
MDC, EGF and sCD40L showed significant increase at 
day 28 compared to day 0 (Table 2).
Association of galectin‑9 with various biomarkers
Numerous cytokines and chemokines were correlated 
with Gal-9 levels in malaria patients at day 0 (Table 3). 
At day 0, IFN-α2 was positively associated with Gal-9 
only in SM cases (rs =  0.82). TNF and IL-6 were posi-
tively correlated with Gal-9 in both UM (rs =  0.57 and 
rs  =  0.36, respectively) and SM cases (rs  =  0.83 and 
rs  =  0.73, respectively). IFN-γ was positively associ-
ated with Gal-9 in both UM (rs  =  0.33) and SM cases 
(rs  =  0.75) (Table  3). IL-10 and IL-1Ra were posi-
tively associated with Gal-9 in both UM (rs = 0.43 and 
rs  =  0.31, respectively) and SM cases (rs  =  0.82; and 
rs = 0.83, respectively).
In addition, Gal-9 was also correlated significantly with 
G-CFS and MIP-1β in both UM (rs = 0.35 and rs = 0.32, 
respectively) and SM cases (rs  =  0.9 and rs  =  0.88, 
respectively). Gal-9 also correlated with MCP-1 in UM 
Table 1 Clinical parameters of uncomplicated and severe malaria patients from day-0 to day-7
Mann–Whitney non-parametric test was used to assess differences between parameters
UM uncomplicated malaria; SM severe malaria
**** P < 0.0001, *** P < 0.001, ** P < 0.01, and * P < 0.05
a Median and range
b Compared UM to SM on day 0
c UM to SM 7
Clinical parametersa Day 0 Day 7
UM SM UM SM
Haemoglobin (g/dL) 11.9 (6–14.4) 11 (6.3–14)b ns 10.3 (6.3–14.2) 8.6 (6.3–9.7)c, **
Direct Bilirubin (mg/dL) 0.29 (0.06–2.6) 0.98 (0.3–5.7)b, *** 0.12 (0.06–0.55) 0.235 (0.1–0.64)c,  *
Platelets (cell/μL) 85.5 (16–502) 27 (16–59)b, ** 249.5 (138–563) 226 (130–429)c ns
Creatinine (mg/dL) 1 (0.6–1.6) 1.25 (1–6.4)b, ** 0.8 (0.5–1.3) 0.775 (0.6–1.15)c ns
BUN (mg/dL) 19.5 (6–56.7) 44.5 (20.3–154.4)b, **** 8.5 (4.5–16.5) 9 (5–12)c ns
AST (U/L) 35 (18–230) 80 (40–295)b, ** 34.00 (12.00–97) 43.50 (20–295)c ns
Sodium (mmol/L) 135 (118–147) 129.5 (118–144)b, * 140 (136–146) 138 (134–144)c ns
Bicarbonate (mmol/L) 22 (15–23) 20 (17–25)b, * 22 (20–26) 21 (21–24)c ns
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group (rs = 0.32) and Fractalkine in SM cases (rs = 0.72) 
(Table 3).
Association of plasma galectin‑9 with clinical parameters 
of malaria infection
Gal-9 levels on day 0 were negatively correlated with 
albumin (rs  =  −0.69), and were positively correlated 
with creatinine (rs  =  0.44) and BUN (rs  =  0.45) in the 
UM cases. The lack of correlation between these kid-
ney parameters and Gal-9 in SM cases might be due to 
the small number of cases in that group (nine patients). 
Among the electrolytes tested, sodium levels were nega-
tively associated with Gal-9 levels (rs = −0.48) also only 
in the UM cases. Chloride levels were negatively associ-
ated with Gal-9 in both UM (rs = −0.46) and SM cases 
(rs  =  −0.73) (Table  4). Furthermore, the Gal-9 median 
level in patients with BUN/creatinine ≥20 (mg/dL) (pre-
renal azotaemia) was significantly higher than those with 
BUN/creatinine <20 (mg/dL) at day 0 (817.3 vs 576.2 pg/
mL) but not at day 7 (Fig. 2). 
Discussion
This study revealed the presence of Gal-9 in plasma in 
malaria patients and showed that plasma levels of Gal-9 
accurately reflect the status of inflammation and recov-
ery during malaria infection for the first time though the 
tissue expression of Gal-9 and Tim-3 was demonstrated 
in murine malaria model [21, 22]. The elevation of Gal-9 
was reported in other acute and non-acute infectious 
diseases such as dengue virus infection (median level 
was 1525  pg/mL), leptospirosis (616  pg/mL) [9], acute 
HIV infection (~2300  pg/mL) [8] and active tubercu-
losis (200  pg/mL) [25]. Detailed analysis with clinical 
parameters in dengue virus infections showed its asso-
ciation with the clinical severity. Gal-9 exerts its pivotal 
immunomodulatory effects by inducing apoptosis or 
suppressing effector functions via engagement with its 
receptor, Tim-3 a co-inhibitory receptor, though how 
Tim-3 functions to determine effector responses have 
not been clarified, yet [14, 15]. The versatile activities of 
























































Fig. 1 Plasma galectin‑9 levels in patients with malaria. a Galectin‑9 kinetics from day 0 to day 28. b Comparison between uncomplicated and 
severe cases, results are expressed as the median. UM uncomplicated malaria, SM severe malaria
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anti-microbial as well as anti-inflammatory activities 
[26].
It has been suggested that Gal-9 production might 
be stimulated by the response of mounting Th1 cells 
that occurs during P. falciparum infection, and pro-
duced Gal-9 was assumed to inhibit their activation [10, 
14]. This may explain the correlation seen in this study 
between Gal-9 and inflammatory cytokines (IFN-γ, TNF, 
IFN-α and IL-6) and chemokines (MIP-1β, MCP-1 and 
Fractalkine) at day 0. It was proposed that the levels of 
TNF and IL-6 are indicators of malaria severity [11]. 
This association of these molecules with Gal-9 in both 
UM and SM cases supports the idea of Gal-9 as a sever-
ity marker in malaria infection. In fact, Gal-9 levels cor-
related positively with kidney parameters and inversely 
with electrolytes.
The correlation of Gal-9 with IL-10 could be related 
to the effect of Gal-9 on differentiation of naïve T cells 
Table 2 Kinetic changes of biomarkers from day-0 to day-28
Results are shown in median levels with range
Friedman test was used to assess differences between days
**** P < 0.0001, *** P < 0.001, ** P < 0.01, and * P < 0.05
a Day 0 vs day 7
b Day 7 vs day 28
c Day 0 vs day 28
Biomarkers Day‑0 (median) Day‑7 (median) Day‑28 (median)
Pro‑inflammatory cytokines
 IFN‑α2 19.95 (2.980–173.9)a, **** 11.92 (2.980–79.51)b ns 8.87 (2.980–70.26)c, ****
 IL‑1α 25.32 (2.77–69.02)a, ** 10.28 (2.44–103.4)b ns 9.63 (2.44–124.9)c, **
 TNF 36.54 (3.91–185.5)**** 10.72 (3.83–74.45)b ns 9.035 (3.89–74.45)c, ****
 IL‑6 55.11 (4.240–1814)a ns 7.57 (4.74–77.81)b ns 11.51 (4.74–77.81)c, **
Th1‑related cytokines
 IFN‑γ 28.6 (3.44–616)a, **** 10.3 (3.14–185.2)b ns 9.2 (3.44–150)c, ****
Regulatory cytokines
 IL‑10 549 (7.94–2321)a, **** 72.66 (3.12–281.9)b, * 20.54 (3.390–2576)c, ****
 IL‑1Ra 109.8 (20.47–1897)a, **** 31.85 (5.47–1358)b ns 19.64 (3.68–595.4)c, ****
 sCD40L 851 (70.01–18,117)a, **** 24,316 (96.21–297,336)b ns 1762 (54.78–200,426)c, ****
Growth cytokines
 G‑CSF 65.85 (6.66–182)a, **** 20.1 (5.38–197)b ns 18.98 (3.93–132.9)c, ****
 GM‑CSF 15.23 (4.420–180)a, * 8.9 (3.810–95)b ns 6.54 (3.090–85.38)c, ****
 EGF 13.72 (4.060–56.37)a, * 23.6 (4.060–482.4) 8b ns 42.17 (6.4–344)c, ****
 FGF‑2 37.05 (13.04–507)a ns 35.51 (8.12–289.2)b, ** 27.29 (4.59–171.8)c, ****
 VEGF 104.1 (23.5–2204)a ns 99.74 (2.24–1754)b ns 77.51 (18.07–3426)c ns
 TGF‑α 4.69 (0.63–21.95)a, * 4.02 (0.29–34.2)b ns 3.18 (0.44–10.49)c, *
Chemokines
 IP‑10 3036 (155–8700)a, **** 671.8 (28.54–1354)b, * ns 449 (110.2–6002)c, ****
 MIP‑1α 25.11 (3.750–85.07)a ns 12.11 (3.780–216)b ns 9.675 (3.47–144.7)c ns
 MIP‑1β 50.8 (13.23–199.8)a, **** 24.78 (4.950–172.5)b ns 25.42 (4.26–187.2)c, ****
 MCP‑1 591.1 (40.67–9148)a, **** 228.2 (50.68–462.7)b, *** 323.9 (52.06–1049)c, *
 IL‑8 35.15 (3.49–227.8)a, * 19.82 (4.05–604)b ns 10.46 (3.65–564)c, *
 Eotaxin 161.3 (21.35–1840)a ns 109.4 (6.54–264.5)b ns 122 (27.25–327)c ns
 GRO 684.6 (184.5–1701)a ns 806.3 (288.8–2962)b ns 799.3 (238.8–1902)c ns
 Fractalkine 77.84 (12.51–546.4)a, **** 25.36 (5.97–533.2)b ns 25.79 (2–340)c, ****
 MDC 284.2 (29.29–1049)a ns 317.8 (64.74–1595)b, **** 502.4 (75.40–801.5)c, ****
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to Gal-9+ ThGal and Treg, which express high levels of 
IL-10 mRNA [27]. Though both Gal-9 and IL-10 were 
proposed to have anti-inflammatory properties, it is 
known that IL-10 production is impaired in SM com-
pared with UM as reported elsewhere [28]. Another 
anti-inflammatory cytokine IL-1Ra levels correlated 
with Gal-9 both in UM and SM cases and IL-1Ra was 
found to be correlated with parasitemia [29]. In malaria, 
a variety immune cells are known to be activated such as 
CD8+ T, CD4+ T and NK cells [30–32], and their func-
tion can be regulated or impaired by Gal-9 in vitro [19, 
33]. However, it is difficult to demonstrate if the released 
Gal-9 could constrain immune response through the 
Gal-9/Tim-3 pathway [19]. Gal-9 shares the receptor 
Tim-3 with high mobility box group-1 (HMBG-1), an 
inflammation mediator [14, 34]. HMGB-1 elevation was 
reported an as informative prognostic marker for dis-
ease severity in human severe malaria [35]. In contrast 
to the apoptotic effect of Gal-9 on T cells [14], HMGB-1 
has been described as having proliferation effects by 
binding through HMGB-1/Tim-3 and HMGB-1/RAGE 
on T cells [36, 37]. The differential roles of these two 
ligands (HMGB-1 and Gal-9) in controlling the immune 
response against parasites should be clarified in future 
studies.
Beside immune modulatory activities, Gal-9 is 
released from infected or damaged cells, and could act 
as danger signal molecules [9], by initiating inflamma-
tion as reported in murine respiratory tularaemia [38]. 
Moreover the Tim-3-Gal-9 expression was found to be 
elevated in acute lung injury in a murine malarial model 
[22].
The released Gal-9 can also bind to galactosides of 
pathogens, pathogen-associated molecular pattern 
(PAMP), as pathogen recognition receptors (PRRs), as 
shown recognition of the Leishmania major Poly-β-
galactosyl epitope by Gal-9 [39]. Future Investigation on 
the biological roles of Gal-9 in malaria infection would be 
necessary.
Conclusions
Taken together, this study shows an increase of plasma 
Gal-9 levels during malaria infection, which is capable of 
identifying severe cases, and is tracking the inflammation 
process. Therefore, it may be used as a novel biomarker 
of malaria infection.
Table 3 Correlation of  galectin-9 with  cytokines 
and chemokines at day 0
Correlation was calculated using a non-parametric Spearman’s correlation test
UM uncomplicated malaria; SM severe malaria
Biomarkers Galectin‑9
UM SM
rs P value rs P value
IFN‑α2 0.21 ns 0.82 0.01
TNF 0.57 0.0001 0.83 0.008
IL‑6 0.36 0.03 0.73 0.03
IFN‑γ 0.33 0.04 0.75 0.02
IP‑10 0.4 0.009 0.65 ns
IL‑8 0.44 0.004 0.88 0.0031
IL‑10 0.43 0.004 0.82 0.01
IL‑1Ra 0.31 0.05 0.83 0.008
G‑CSF 0.35 0.03 0.9 0.002
MIP‑1β 0.32 0.04 0.88 0.003
MCP‑1 0.32 0.04 0.55 ns
Fractalkine 0.27 ns 0.72 0.04
Table 4 Correlation between  galectin-9 and  clinical 
parameters
Correlation was calculated using a non-parametric Spearman’s correlation test. rs 
value represents correlation coefficient. P value represents significance level
UM uncomplicated malaria; SM severe malaria
Clinical parameter Galectin‑9
UM SM
rs P value rs P value
Albumine −0.69 <0.0001 −0.29 ns
Creatinine 0.44 0.005 0.32 ns
BUN 0.45 0.004 0.43 ns
AST 0.46 0.003 0.55 ns
Sodium −0.48 0.005 −0.25 ns
Chloride −0.46 0.006 −0.73 0.04
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UM: uncomplicated malaria; SM: severe malaria; Gal‑9: galectin‑9; Tim‑3: T cell 
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tumour necrosis factor; IFN: interferon; IP‑10: interferon inducible protein 10; 
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factor; MIP: macrophage inflammatory protein; MDC: macrophage‑derived 
chemokine; MCP: monocyte chemoattractant protein; TGF: transforming 
growth factor; EGF: epidermal growth factor; sCD40L: soluble cluster of dif‑
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